About XA+ NHL
X-antigen-positive (XA+) non-Hodgkin’s lymphoma (NHL) is a particularly aggressive subtype of NHL, with a poor prognosis1
XA+ NHL is an aggressive subtype with rapid progression and a low survival rate.1
5-year survival rate
Symptoms are similar to other types of NHL; however, the XA+ subtype progresses quickly, so patients are likely to be diagnosed at a later stage.1
Current treatments do not effectively target malignant cells and therefore have high toxicity1
- Unlike in other types of NHL, monoclonal antibody treatments show poor efficacy in XA+ subtypes and are generally not used.1
- Chemotherapy is the standard of care, but has limited efficacy and high toxicity.1
1 in 4
XA+ NHL patients discontinue chemotherapy due to adverse events.1